|
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study. |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); IPSEN (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
Speakers' Bureau - Amgen (Inst); Astellas Pharma (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Sanofi/Aventis (Inst) |
Research Funding - BMS (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Merck KGaA; Pfizer |
Travel, Accommodations, Expenses - Astellas Oncology; Bristol-Myers Squibb; Ipsen; MSD; Pfizer |
|
|
Consulting or Advisory Role - Amgen; amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); BMS (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; ipsen; ipsen; ipsen; Janssen-Cilag; pfizer; Roche |
Other Relationship - Janssen |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Pfizer/Astellas |
|
|
Honoraria - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer |
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Eisai; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; MSD; Pfizer |
|
|
|
Consulting or Advisory Role - Pfizer |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Merck Serono; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer; Pfizer; Pfizer; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Ipsen; Janssen |
Consulting or Advisory Role - Ipsen; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AC BioScience; CellProthera; Fondazione Smith Kline; Gercor; HalioDx; Incyte; Invectys; Janssen-Cilag; OSE Immunotherapeutics; Pfizer |
Travel, Accommodations, Expenses - MSD |
|
|
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |